NGNE - NASDAQ

Neurogene Inc.

NGNE·NASDAQ

$27.53

+5.3%

HealthcareBiotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$435.04M

EPS-4.2400

P/E Ratio-6.49

Earnings Date08/07/2026

ngne

Total Liabilities and Equity

Last Annual Value

288.60M

3-Year CAGR

38%

5-Year CAGR

10-Year CAGR

10%

Adjust for Inflation

Neurogene Inc. Competitors Analysis of Total Liabilities and Equity

NGNE · NASDAQ

Company	Total Liabilities and Equity	CAGR 3Y	CAGR 5Y	CAGR 10Y
Neurogene Inc. NASDAQ:NGNE	288.60M	9.0%	23.2%	6.5%
Ocugen, Inc. NASDAQ:OCGN	43.52M	-12.3%	-16.3%	1.9%
Alumis Inc. Common Stock NASDAQ:ALMS	411.94M	66.3%	N/A	N/A
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT	330.45M	-16.4%	-7.8%	9.8%
4D Molecular Therapeutics, Inc. NASDAQ:FDMT	566.71M	18.6%	9.9%	N/A
Inhibrx Biosciences, Inc. NASDAQ:INBX	146.48M	-21.9%	-0.5%	21.3%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	385.14M	66.0%	N/A	N/A
Benitec Biopharma Inc. NASDAQ:BNTC	99.59M	181.5%	36.0%	21.0%
Lineage Cell Therapeutics, Inc. AMEX:LCTX	112.58M	3.7%	-8.4%	-2.3%
PureTech Health plc NASDAQ:PRTC	534.71M	-8.3%	-10.8%	6.0%
Fulcrum Therapeutics, Inc. NASDAQ:FULC	366.28M	12.4%	9.3%	N/A

Neurogene Inc. Fair Value Envelope

NGNE · NASDAQ

Our analysis suggests that NGNE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.531, this represents a potential HIDDEN relative to our calculated worth for Neurogene Inc..

HIDDEN

Intrinsic Value

Current Price: $27.531

Related Guides

Blog Categories

Continue your NGNE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.